Rivas Medical Weight Loss review

The costs at a glance

Telehealth has a clear introductory and ongoing split

Rivas advertises a $195 first month for its compounded telehealth programs, including the initial evaluation and medication. Ongoing compounded semaglutide is $399 monthly and tirzepatide is $599 monthly, with visits and shipping included. I would evaluate the introductory saving against the following months, when the main cost difference appears. Confirm which medication the first-month offer covers and whether any testing is separately required. A clinician can recommend a different approach after reviewing your history, so the advertised starting payment should not become a promise of a particular prescription. Ask for the complete schedule before selecting a visit. Our total-cost guide helps compare the introductory month and recurring bill.

Office treatment uses weeks rather than calendar months

The office pricing page lists semaglutide at $115 weekly, $437 for four weeks or $1,242 for twelve weeks. Those packages include medication and visits. Four weekly payments total $460, so the four-week package saves $23 against that specific comparison. It does not represent a calendar-month subscription. If you intend to attend regularly, include travel time and missed-work costs as well as the treatment bill. Someone who values face-to-face checks may find those visits useful; someone traveling far may see a different value equation. Keep the office pathway beside the video pathway rather than blending their prices. See the 28-day billing guide before comparing a four-week package with monthly care.

The initial office fee is a different purchase

Rivas describes a $195 initial office visit as an entry into lifetime membership, with an annual-visit condition for avoiding another initial fee. That is distinct from the telehealth first-month promotion. I would ask the office to explain exactly what happens if you return after a long gap or move between visit formats. A familiar dollar amount can obscure different inclusions, and the word lifetime does not remove a stated maintenance condition. Save the policy you are given with your evaluation receipt. It is easier to understand the continuing relationship before starting than to reconstruct it after an interruption.

Brand prescriptions have a separate pharmacy bill

Rivas also offers a $100 monthly follow-up visit for a Wegovy or Zepbound prescription, with the medication purchased separately at a pharmacy. Insurance may help with the prescription, but that does not make the $100 figure an all-in treatment price. I would ask my insurer about the named product and my diagnosis, then request a pharmacy estimate before deciding. Include any remaining visit responsibility in that calculation. This is a useful option to compare when you want a manufacturer product and continuing care, but the apparent savings disappear if you compare a consultation fee with a complete compounded package.

Regional access is concrete and worth checking

The telehealth page identifies Maryland, Virginia and Florida and says patients must be located in a served state for their appointment. That specificity is useful for anyone who travels or spends part of the year elsewhere. I would tell the scheduling team about that pattern before booking and ask how it affects follow-up. A nearby office is also relevant when you want the option to change visit format, but the practical arrangement should be confirmed with your actual clinic. General brand familiarity cannot establish prescribing permission at the place where you will be sitting during a video visit. Use our travel and telehealth guide to prepare location questions.

The visit is part of the value proposition

Rivas frames telehealth around a live provider conversation and ongoing support, rather than a prescription based only on a submitted form. Its FAQ is a useful companion when preparing questions about the practice. I would arrive with a medication list, relevant records and a clear explanation of what has or has not worked previously. Ask which follow-up measurements matter and how a concern is escalated between appointments. A scheduled conversation is valuable when it produces decisions you understand. It should leave you knowing the next review date, the care contact and what the clinician wants monitored before that review.

No contract still leaves package questions

Rivas advertises no contracts and cancellation flexibility. I would still ask what happens to a prepaid four- or twelve-week package if a clinician stops treatment, you relocate or attending becomes impractical. Ending future visits and recovering money already paid are separate issues. Financing can add another payment relationship, so compare its total cost and cancellation treatment before accepting it. A useful written answer should identify remaining services, any amount refundable and the effective date of the change. Flexible scheduling is an advantage only when the financial consequences of changing the plan are equally understandable.

My assessment: choose the format you will actually use

Rivas makes a stronger case for readers who appreciate regular clinician contact or can use its regional clinics. I would not choose it solely by the introductory $195 amount, because the ongoing video rate and the office schedule create different budgets. Readers interested in another consultation-first comparison can look at Sesame Care; Found provides another structured medical weight-management model to examine. Ask each about the same prescription type and frequency of clinical contact. The most useful comparison is the full arrangement you will continue using, including the time spent attending care and the cost after any initial promotion ends.

Before you sign up

• Am I choosing telehealth or an office package?
• Does the $195 first-month offer cover my prescribed compounded treatment?
• What are unused-package and yearly membership conditions?

Use the answers to compare the exact offer with another provider. A service review cannot determine whether a medication is appropriate for you; that decision belongs with your clinician.